Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T Program at the 59th American Society of Hematology Annual Meeting
In the oral presentation,
ASH Presentations on Bellicum Programs
BPX-501:
Oral Presentation: “Donor T Cells Genetically Modified with a Novel Suicide Gene (Inducible Caspase 9, iC9) Expand and Persist Over Time After Post-Allograft Infusion in Patients Given αβ T-Cell and B-Cell Depleted HLA-Haploidentical Allogeneic Stem Cell Transplantation (αβ Haplo-HSCT) Contributing to Accelerate Immune Recovery”
Abstract Number: 211
Session Name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Prevention
Session Date: Saturday, December 9, 2017
Session Time: 2:
Presentation Time: 2:00 p.m. EST
Controllable CAR-T Technology:
Poster Presentation: “Dual-Switch CAR-T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123+ Cancer”
Abstract Number: 3184
Session Name: 703. Adoptive Immunotherapy: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:00 p.m. - 8:00 p.m. EST
Poster Presentation: “Inducible MyD88/CD40 (iMC) Costimulation Enhances Polyclonal Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte (EBV-CTL) Proliferation and Anti-Tumor Activity”
Abstract Number: 3337
Session Name: 801. Gene Therapy and Transfer: Poster II
Date: Sunday, December 10, 2017
Presentation Time: 6:
Poster Presentation: “MyD88/CD40 Enhanced CD19-Specific CAR-T Cells Maintain Therapeutic Efficacy Following Resolution of Cytokine-Related Toxicity Using Inducible Caspase-9”
Abstract Number: 4615
Session Name: 801. Gene Therapy and Transfer: Poster III
Date: Monday, December 11, 2017
Presentation Time: 6:
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including allogeneic hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Source:
Investors:Bellicum Pharmaceuticals, Inc. Alan Musso , CFO 832-384-1116 amusso@bellicum.com Media:BMC Communications Brad Miles 646-513-3125 bmiles@bmccommunications.com
Source: Bellicum Pharmaceuticals, Inc.